Program
608
Also written as “608 Q2W”, “608 Q4W” and “608 dose”.
Its studies are mostly in Psoriasis · Non-Radiographic Axial Spondyloarthritis · Spondylitis, Ankylosing, led by 3SBio.
Furthest: phase 3, since Sep 8, 20227 company-led studies, 5 open or runningNext primary completion: Jan 14, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| 3SBio | 75 open or running | phase 3since Sep 8, 2022 | Apr 25, 2020 | Jan 14, 2027phase 3 · NCT07261644 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 25, 2020First study: phase 1 study in Moderate to Severe Plaque PsoriasisFirst studyNCT04367441 · 62 enrolled · China
- Sep 8, 2022Phase 3 study in PsoriasisNCT05536726 · 458 enrolled · China
- Jan 10, 20242 phase 2 studiesNCT06222671, NCT06242652
- Feb 28, 2024Phase 3 study in Plaque Psoriasis PatientsNCT06299982 · 750 planned
- Nov 21, 2025Phase 3 study in Spondylitis, AnkylosingNCT07261644 · 500 planned · China
- Jan 9, 2026Phase 3 study in Non-Radiographic Axial SpondyloarthritisNCT07349329 · 380 planned · China
Ahead
- Jan 14, 2027Primary completion: phase 3 study in Spondylitis, AnkylosingNCT07261644
- Apr 19, 2028Primary completion: phase 3 study in Non-Radiographic Axial SpondyloarthritisNCT07349329
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07349329Non-Radiographic Axial Spondyloarthritis · China | 3 | Not yet recruiting | Apr 19, 2028 | 380 |
| NCT07261644Spondylitis, Ankylosing · China | 3 | Recruiting | Jan 14, 2027 | 500 |
| NCT06299982Plaque Psoriasis Patients | 3 | Not yet recruiting | Jan 30, 2025 | 750 |
| NCT06242652Spondylitis, Ankylosing · China | 2 | Active, not recruiting | Feb 27, 2025 | 250 |
| NCT06222671Axial Spondyloarthritis · China | 2 | Recruiting | Sep 22, 2025 | 180 |
| NCT05536726Psoriasis · China | 3 | Completed | Oct 20, 2023 | 458 |
| NCT04367441Moderate to Severe Plaque Psoriasis · China | 1 | UNKNOWN | Oct 31, 2020 | 62 |
How it is read
Names in the registry
- “608”, 4 entries
- “608 Q2W”, 2 entries
- “608 Q4W”, 2 entries
- “608 dose”, 1 entry
- “608 Dose A”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 3 studies
- Non-Radiographic Axial Spondyloarthritis, 2 studies
- Spondylitis, Ankylosing, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.